- Home
- MFH vs SGMT Comparison
MFH vs SGMT Comparison
Compare MFH & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- SGMT
- Stock Information
- Founded
- MFH 2011
- SGMT 2006
- Country
- MFH United States
- SGMT United States
- Employees
- MFH N/A
- SGMT N/A
- Industry
- MFH Finance: Consumer Services
- SGMT
- Sector
- MFH Finance
- SGMT
- Exchange
- MFH Nasdaq
- SGMT Nasdaq
- Market Cap
- MFH 249.7M
- SGMT 269.2M
- IPO Year
- MFH N/A
- SGMT 2023
- Fundamental
- Price
- MFH $4.30
- SGMT $7.67
- Analyst Decision
- MFH
- SGMT Strong Buy
- Analyst Count
- MFH 0
- SGMT 8
- Target Price
- MFH N/A
- SGMT $27.25
- AVG Volume (30 Days)
- MFH 1.7M
- SGMT 774.2K
- Earning Date
- MFH 08-26-2025
- SGMT 08-13-2025
- Dividend Yield
- MFH N/A
- SGMT N/A
- EPS Growth
- MFH N/A
- SGMT N/A
- EPS
- MFH N/A
- SGMT N/A
- Revenue
- MFH N/A
- SGMT N/A
- Revenue This Year
- MFH N/A
- SGMT N/A
- Revenue Next Year
- MFH N/A
- SGMT N/A
- P/E Ratio
- MFH N/A
- SGMT N/A
- Revenue Growth
- MFH 125.92
- SGMT N/A
- 52 Week Low
- MFH $1.03
- SGMT $1.73
- 52 Week High
- MFH $8.86
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- MFH 56.20
- SGMT 39.43
- Support Level
- MFH $3.72
- SGMT $8.62
- Resistance Level
- MFH $4.45
- SGMT $10.06
- Average True Range (ATR)
- MFH 0.52
- SGMT 0.74
- MACD
- MFH 0.07
- SGMT -0.17
- Stochastic Oscillator
- MFH 57.14
- SGMT 0.38
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.